AskBio Declares Independence After Bayer Acquisition

Will Not Be Hamstrung By Bureaucracy

The gene therapy specialist's CEO Sheila Mikhail tells Scrip she is excited to be getting access to the German group's late-stage clinical and operational expertise while keeping AskBio's entrepreneurial culture and carrying on as an autonomous company on an arm’s-length basis.

3d people - man, person with a financial chart . Businessmen and different part
AskBio will operate as a separate unit of Bayer • Source: Shutterstock

More from Gene Therapies

More from Advanced Therapies